Microglial activation positively correlates with tau burden in transgenic mice and tauopathy patients (Yoshiyama et al., 2007; Serrano-Pozo et al., 2011), and predicts cognitive decline and clinical severity in AD patients (Edison et al., 2008; Malpetti et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.